Neurodyn Cognition Inc. is a spin-out company of Neurodyn Life Sciences Inc. – a special purpose company established to commercialize Memogain®
- A next generation pro-drug of an approved AD drug (Reminyl)
- Alpha-7 potentiation – main mechanism
- No side effects, high brain delivery
- Potent disease modification demonstrated pre-clinically
- Potential rapid EU approval
Get the latest on Neurodyn Cognition from CEO, Kenneth Cawkell, in this feature presentation at Noble Capital Markets’ 14th Annual Investor Conference.